1. Scrip
  2. >>Business

Shire Outlines Baxalta Integration Strategy

 
• By Joseph Haas

First quarter financial results brought another growth period for Shire PLC, but perhaps the most noteworthy information provided by the company on its April 29 earnings call, was its strategy for integrating Baxalta Inc. into its infrastructure, assuming both companies' boards approve the transaction when they meet separately on May 27.

Overall, the Dublin-headquartered specialty firm reported product sales of $1.627bn for the first quarter of 2016, up 14% year-over-year. As usual, the top-seller was attention-deficit/hyperactivity disorder (ADHD) stalwart Vyvanse (lisdexamfetamine), which posted 22% growth to $509m on the quarter. It also was a strong quarter for Shire's hereditary angioedema franchise, as Firazyr (icatibant) sales increased 39% to $128m and Cinryze (C1 esterase inhibitor) sales rose 11% to $164m.

Initially launched as a hostile bid in mid-2015, Shire's acquisition of Baxalta was agreed upon in January at a price...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By Joseph Haas

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 
• By Jessica Merrill

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By Kevin Grogan

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By Aakash Babu

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.